Oncorus Executives
| ONCRDelisted Stock | USD 0.04 0.01 14.71% |
Oncorus employs about 64 people. The company is managed by 6 executives with a total tenure of roughly 150 years, averaging almost 25.0 years of service per executive, having 10.67 employees per reported executive. Discussion of Oncorus' management performance can provide insight into the enterprise performance.
Oncorus |
Oncorus Management Team Effectiveness
The company has return on total asset (ROA) of (0.3224) % which means that it has lost $0.3224 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2456) %, meaning that it created substantial loss on money invested by shareholders. Oncorus' management efficiency ratios could be used to measure how well Oncorus manages its routine affairs as well as how well it operates its assets and liabilities.Oncorus Workforce Comparison
Oncorus is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 332. Oncorus retains roughly 64.0 in number of employees claiming about 19% of stocks in Biotechnology industry.
Oncorus Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncorus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncorus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Oncorus insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brian Shea over a year ago OncorusInc exotic insider transaction detected | ||
Morrison Briggs over a year ago OncorusInc exotic insider transaction detected |
Oncorus Notable Stakeholders
An Oncorus stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oncorus often face trade-offs trying to please all of them. Oncorus' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oncorus' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard MBA | Chief CFO | Profile | |
| Brian Shea | Director Sec | Profile | |
| Chris German | Controller | Profile | |
| Stephen Harbin | COO Staff | Profile | |
| Mitchell Finer | NonEx Chairman | Profile | |
| John MD | Chief Officer | Profile |
About Oncorus Management Performance
The success or failure of an entity such as Oncorus often depends on how effective the management is. Oncorus management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncorus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncorus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Oncorus operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Oncorus Workforce Analysis
Traditionally, organizations such as Oncorus use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oncorus within its industry.Oncorus Manpower Efficiency
Return on Oncorus Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 12.9M | |
| Working Capital Per Employee | 428.3K | |
| Working Capital Per Executive | 4.6M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Oncorus Stock
If you are still planning to invest in Oncorus check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncorus' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |